Functional Tumor Targeting Nano‐Systems for Reprogramming Circulating Tumor Cells with In Situ Evaluation on Therapeutic Efficiency at the Single‐Cell Level
Source abstract
Abstract
Abstract Tumor heterogeneity is primarily responsible for treatment resistance and cancer relapses. Being critically important to address this issue, the timely evaluation of the appropriateness of therapeutic actions at the single‐cell level is still facing challenges. By using multi‐functionalized nano‐systems with the delivery vector composed of histone for plasmids loading, hyaluronic acid for tumor targeting, and a fusion peptide for C‐X‐C motif chemokine receptor 4 (CXCR4) targeting as well as nuclear localization, the reprogramming of circulating tumor cells (CTCs) with in situ detection on biomarkers at the single‐cell level is realized. By efficient co‐delivery of the genome editing plasmid for CXCR4 knockout and molecular beacons for detection of upregulated mRNA biomarkers into CTCs in unprocessed whole blood, the therapeutic outcomes of genome editing at the single‐cell level can be in situ evaluated. The single‐cell analysis shows that CXCR4 in CTCs of cancer patients is efficiently downregulated, resulting in upregulated anticancer biomarkers such as p53 and p21. The study provides a facile strategy for in‐depth profiling of cancer cell responses to therapeutic actions at single‐cell resolution to evaluate the outcomes of treatments timely and conveniently.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · CAR-T cell therapy research · Single-cell and spatial transcriptomics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Biomedical Polymers of Ministry of Education Department of Chemistry Wuhan University Wuhan 430072 P. R. China
School of Life Sciences Anhui Medical University Hefei 230032 P. R. China
Funding
National Natural Science Foundation of China
References (51)
Show source-provided references
1. 10.1038/s41576-019-0114-610.1038/s41576-019-0114-6 ↗
2. 10.1038/nrclinonc.2017.16610.1038/nrclinonc.2017.166 ↗
3. 10.1038/s41568-019-0180-210.1038/s41568-019-0180-2 ↗
4. 10.7150/thno.3433710.7150/thno.34337 ↗
5. 10.1073/pnas.190790411610.1073/pnas.1907904116 ↗
6. 10.1016/j.addr.2020.04.01010.1016/j.addr.2020.04.010 ↗
7. 10.1038/nature1976410.1038/nature19764 ↗
8. 10.1016/j.biomaterials.2019.11971110.1016/j.biomaterials.2019.119711 ↗
9. 10.1038/nrd.2017.9110.1038/nrd.2017.91 ↗
10. 10.1158/0008-5472.CAN-17-045410.1158/0008-5472.CAN-17-0454 ↗
11. 10.1038/leu.2008.29910.1038/leu.2008.299 ↗
12. 10.1182/blood-2006-05-02484410.1182/blood-2006-05-024844 ↗
13. 10.1158/1078-0432.CCR-09-232910.1158/1078-0432.CCR-09-2329 ↗
14. 10.1038/sj.onc.120691010.1038/sj.onc.1206910 ↗
15. 10.4161/cbt.3.1.54710.4161/cbt.3.1.547 ↗
16. 10.1002/hep.2766510.1002/hep.27665 ↗
17. 10.1038/s41591-020-0880-x10.1038/s41591-020-0880-x ↗
18. 10.1016/j.biomaterials.2015.04.03010.1016/j.biomaterials.2015.04.030 ↗
19. 10.1016/j.jconrel.2015.12.05210.1016/j.jconrel.2015.12.052 ↗
20. 10.1016/j.cell.2013.06.04410.1016/j.cell.2013.06.044 ↗
21. Zheng F. · Anticancer Res. · 2017 · 37 · 4361
22. 10.1007/s12013-019-00898-x10.1007/s12013-019-00898-x ↗
23. 10.2147/OTT.S19566110.2147/OTT.S195661 ↗
24. 10.1016/j.jconrel.2022.02.01210.1016/j.jconrel.2022.02.012 ↗
25. 10.1021/acs.chemrev.6b0079910.1021/acs.chemrev.6b00799 ↗
26. 10.1016/j.addr.2020.03.00110.1016/j.addr.2020.03.001 ↗
27. 10.1002/advs.20200142410.1002/advs.202001424 ↗
28. 10.1126/sciadv.abg321710.1126/sciadv.abg3217 ↗
29. 10.1002/anie.20211656910.1002/anie.202116569 ↗
30. 10.1002/adma.20210464110.1002/adma.202104641 ↗
31. 10.1016/j.nantod.2021.10135910.1016/j.nantod.2021.101359 ↗
32. 10.1002/adma.20200600310.1002/adma.202006003 ↗
33. 10.1002/adfm.20200494010.1002/adfm.202004940 ↗
34. 10.1016/j.bios.2021.11340110.1016/j.bios.2021.113401 ↗
35. 10.1016/j.biotechadv.2018.11.00910.1016/j.biotechadv.2018.11.009 ↗
36. 10.1002/adma.20200020810.1002/adma.202000208 ↗
37. 10.1002/advs.20210029210.1002/advs.202100292 ↗
38. Unzueta U. · Int. J. Nanomed. · 2012 · 7 · 4533
39. 10.1016/j.jconrel.2018.01.03110.1016/j.jconrel.2018.01.031 ↗
40. 10.1073/pnas.96.1.9110.1073/pnas.96.1.91 ↗
41. 10.1038/mt.2011.25710.1038/mt.2011.257 ↗
42. 10.1074/jbc.M113.44992610.1074/jbc.M113.449926 ↗
43. 10.1016/j.canlet.2015.07.01910.1016/j.canlet.2015.07.019 ↗
44. 10.3892/mmr.2016.504810.3892/mmr.2016.5048 ↗
45. 10.1038/nrc265710.1038/nrc2657 ↗
46. 10.1158/1541-7786.MCR-10-038610.1158/1541-7786.MCR-10-0386 ↗
47. 10.1007/s12035-014-8935-y10.1007/s12035-014-8935-y ↗
48. 10.1016/j.cellsig.2020.10967210.1016/j.cellsig.2020.109672 ↗
49. 10.1038/3506501610.1038/35065016 ↗
50. 10.1007/s12035-015-9340-x10.1007/s12035-015-9340-x ↗
51. 10.1073/pnas.181551511610.1073/pnas.1815515116 ↗